Benzinga | May 5, 2021 04:35PM EDT

ACADIA Pharmaceuticals Reaffirms FY21 NUPLAZID Net Sales Guidance O $510M-$550M

* Acadia is reiterating its NUPLAZID net sales guidance of $510 to $550 million.

* GAAP R&D guidance is decreased to $280 to $300 million from the previous range of $300 to $320 million. Current R&D guidance includes approximately $25 million of stock-based compensation expense.

* GAAP SG&A guidance is decreased to $385 to $415 million from the previous range of $560 to $590 million. Previous guidance included additional investments associated with the potential DRP launch in 2021 and updated guidance reflects a reduction in these expenses. Current SG&A guidance includes approximately $50 million of stock-based compensation expense.